Abstract
1. Heterozygous, male, hypertensive, transgenic ((mRen-2)27) rats (350-450 g) were instrumented for the measurement of regional or cardiac haemodynamics (n = 16, in both groups). Animals were given continuous i.v. infusions of the angiotensin-converting enzyme inhibitor, enalaprilat, or the dual metallopeptidase inhibitor, MDL 100,240 (both at 3 mg kg-1, 3 mg kg-1 h-1; n = 8 for regional and cardiac haemodynamics), for 32 h. Twenty four hours after the onset of infusion of enalaprilat or MDL 100,240, the bradykinin (B2)-receptor antagonist, Hoe 140 (1 mg kg-1, i.v.), was given and measurements were continued for a further 8 h, to assess any possible involvement of bradykinin. 2. Over the first 8 h of infusion, both enalaprilat and MDL 100,240 had significant antihypertensive effects, accompanied by similar regional vasodilatations. However, the blood pressure lowering effect of MDL 100,240 (-54 +/- 9 mmHg) was greater than that of enalaprilat (-38 +/- 4 mmHg), because the former caused a significantly greater reduction in cardiac index. 3. Between 8-24 h after the onset of infusion, there was a reduction in the effect of enalaprilat on blood pressure, because cardiac index rose, with no further increase in total peripheral cond...Continue Reading
References
Jul 1, 1992·Hypertension·G BaoT Unger
Mar 1, 1991·British Journal of Pharmacology·K WirthJ Knolle
Dec 1, 1992·Circulation Research·A M RichardsC Frampton
Jun 1, 1992·Hypertension·M BaderD Ganten
Jan 1, 1990·Journal of Cardiovascular Pharmacology·E G Erdös
Mar 1, 1991·Journal of Cardiovascular Pharmacology·A A SeymourB Abboa-Offei
Jul 23, 1991·European Journal of Pharmacology·G BaoT Unger
Feb 28, 1991·Biochemical and Biophysical Research Communications·J A NormanG Di Donato
Nov 1, 1990·British Journal of Pharmacology·S M GardinerT Bennett
Oct 1, 1990·Hypertension·L DanckwardtT Unger
Oct 1, 1990·Clinical Science·A F MullerT Bennett
Apr 5, 1990·Nature·J J MullinsD Ganten
Mar 1, 1988·Hypertension·L F CarbonellA G Scicli
Nov 1, 1986·Hypertension·A BenetosI Gavras
Jul 1, 1995·Journal of Cardiovascular Pharmacology·J F FrenchR C Dage
Jan 1, 1995·Fundamental & Clinical Pharmacology·I PhamJ B Michel
Oct 14, 1994·Biochemical and Biophysical Research Communications·S De LombaertR L Webb
Apr 1, 1993·The Biochemical Journal·A J KennyJ Ingram
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·M C Fournié-ZaluskiJ B Michel
May 1, 1994·Hypertension·T L StevensJ C Burnett
May 1, 1994·Hypertension·C Hirth-DietrichF C Luft
Oct 1, 1995·British Journal of Pharmacology·S M GardinerT Bennett
Jan 1, 1996·Hypertension·K ChenB G Zimmerman
May 1, 1996·Clinical Science·T SupapornJ C Burnett
Jun 1, 1996·Journal of Hypertension·M LuqueC M Ferrario
Feb 5, 1996·European Journal of Pharmacology·I PhamJ B Michel
Nov 1, 1996·Journal of Hypertension·R Reneland, L Berglund
Jul 1, 1997·British Journal of Clinical Pharmacology·D J Webb
Jan 10, 1998·British Journal of Pharmacology·S M GardinerT Bennett
Citations
Jun 16, 2001·British Journal of Pharmacology·V ArbinJ Peyroux
Dec 10, 2003·British Journal of Pharmacology·Sheila M GardinerTerence Bennett
Dec 18, 2003·British Journal of Clinical Pharmacology·Matthew I WorthleyStephen G Worthley
Jul 20, 2002·Journal of Hypertension·Gian Paolo RossiAchille C Pessina
Feb 22, 2003·Cardiovascular Drug Reviews·Gian Paolo Rossi
Feb 28, 2002·American Journal of Hypertension·Gian Paolo RossiAchille C Pessina
Sep 23, 2003·Drugs·Reza Tabrizchi